Quest Diagnostics Launches Self-Collection for HPV Testing

Quest Diagnostics Launches Self-Collection for HPV Testing
Providers may now order the FDA-cleared HPV self-collection solution for their patients to use in healthcare environments. This initiative aims to reduce barriers to screening by facilitating discreet self-collection options.
Quest Diagnostics plans to make this self-collection service available at its extensive network of 2,000 patient service centers, significantly expanding access to essential screenings.
The introduction of the HPV self-collection builds upon Quest's previous success with a similar self-collection solution for various STIs, which was launched last fall. This new offering allows women to take control of their health by identifying HPV, a significant risk factor for cervical cancer.
On April 2, 2025, Quest Diagnostics announced its commitment to enhancing healthcare access by enabling self-collection of HPV specimens, marking a crucial advance in women’s health services.
The new self-collection option allows patients to collect specimens discreetly in a physician's office. Plans are underway to expand the availability of this option to patients at numerous Quest service centers nationwide. This development is particularly important given the increasing need for accessible healthcare solutions.
Inspired by the need for accessible cervical cancer screenings, Quest's self-collection service encourages women to participate in their health care actively. More than 4,000 women in the country are expected to lose their lives to cervical cancer each year, primarily due to insufficient screening. This service aims to provide women with the tools they need to undergo routine tests.
While the solution is specifically designed for healthcare settings, it is crucial to understand that it is not approved for at-home collection. Patients who suspect they are pregnant or have experienced symptoms of infection should consult their healthcare provider for understanding and assistance during self-collection.
Improving Access to Reduce Cervical Cancer Incidence
In traditional practices, healthcare providers collect specimens from patients in their offices and test them in laboratories. The new self-collection option allows patients to collect specimens privately, making the process more comfortable and less intimidating.
As women continue to express varying levels of comfort regarding gynecological exams, providing choices, including self-collection, has become essential. According to Dr. Damian P. Alagia, a board-certified obstetrician and gynecologist, co-testing remains the most reliable method for cervical cancer detection, but the preferences of patients must also be acknowledged.
Data indicates a significant drop in screening rates due to factors like the COVID-19 pandemic. Consequently, there is an urgent need for innovative strategies to encourage screening among populations historically underserved in healthcare.
Recent guidelines from the United States Preventive Services Task Force highlight that self-collection for HPV screening has similar efficacy to clinician-collected tests. This means more women may now feel confident participating in routine cancer screenings.
Quest Diagnostics remains at the forefront of women's health, offering a comprehensive range of solutions to ensure timely screenings and accurate diagnoses. Learn more about these health solutions on their dedicated women's health portal.
About Quest Diagnostics
Quest Diagnostics is dedicated to creating a healthier world, one person at a time. The company offers diagnostic insights that empower individuals, health professionals, and organizations to improve health outcomes. With a vast database of clinical lab results, Quest continually explores new avenues to enhance disease detection and treatment, fostering healthy behaviors and effective healthcare management. Serving one in three adults in America, Quest is committed to using diagnostic insights to enact meaningful change in health and well-being.
Frequently Asked Questions
1. What is the new HPV self-collection service by Quest Diagnostics?
The HPV self-collection service allows patients to collect their specimens in a private setting, such as a physician’s office, enabling discreet access to screening.
2. How does self-collection improve cervical cancer screening access?
By providing discreet and convenient options for self-collection, more women are likely to participate in screenings, thus increasing early detection rates for cervical cancer.
3. Is at-home self-collection allowed with this service?
No, self-collection is intended for use in healthcare settings and is not FDA-approved for at-home use due to safety and efficacy considerations.
4. How does this service benefit women who are uncomfortable with traditional methods?
This self-collection service addresses discomfort and stigma associated with traditional collection methods, allowing patients to take control of their health in a comfortable environment.
5. Why is cervical cancer screening crucial?
Routine cervical cancer screening is vital as it can lead to early detection and treatment, ultimately reducing the risk of cervical cancer development and enhancing women's overall health outcomes.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.